Zealand Pharma A/S (ZEAL) — Net Asset Quality Index
Zealand Pharma A/S (ZEAL) has a Net Asset Quality Index of 90.1% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Dkr16.46 Billion minus total liabilities of Dkr1.63 Billion yields net assets of Dkr14.83 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Zealand Pharma A/S balance sheet liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zealand Pharma A/S Net Asset Quality Index Over Time (2007–2025)
This chart shows how Zealand Pharma A/S's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of December 2025, the index stands at 90.1%, representing net assets of Dkr14.83 Billion against total assets of Dkr16.46 Billion DKK. For live market cap and overall valuation, see ZEAL market cap.
Annual Net Asset Quality Index for Zealand Pharma A/S (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Zealand Pharma A/S from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check strategic asset allocation of Zealand Pharma A/S to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (DKK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.1% | Dkr14.83 Billion | Dkr16.46 Billion | Dkr1.63 Billion | ▼ -0.6 pp |
| 2024 | 90.6% | Dkr8.62 Billion | Dkr9.51 Billion | Dkr888.86 Million | ▲ +10.2 pp |
| 2023 | 80.4% | Dkr1.59 Billion | Dkr1.98 Billion | Dkr387.15 Million | ▲ +27.5 pp |
| 2022 | 53.0% | Dkr815.91 Million | Dkr1.54 Billion | Dkr723.89 Million | ▲ +8.1 pp |
| 2021 | 44.9% | Dkr927.80 Million | Dkr2.07 Billion | Dkr1.14 Billion | ▼ -16.3 pp |
| 2020 | 61.2% | Dkr1.18 Billion | Dkr1.92 Billion | Dkr747.52 Million | ▼ -16.5 pp |
| 2019 | 77.7% | Dkr1.24 Billion | Dkr1.60 Billion | Dkr356.84 Million | ▼ -13.1 pp |
| 2018 | 90.8% | Dkr1.12 Billion | Dkr1.23 Billion | Dkr113.52 Million | ▲ +19.1 pp |
| 2017 | 71.7% | Dkr528.47 Million | Dkr737.24 Million | Dkr208.77 Million | ▲ +31.6 pp |
| 2016 | 40.0% | Dkr278.19 Million | Dkr694.63 Million | Dkr416.43 Million | ▲ +0.3 pp |
| 2015 | 39.7% | Dkr252.23 Million | Dkr634.69 Million | Dkr382.46 Million | ▼ -2.6 pp |
| 2014 | 42.4% | Dkr252.83 Million | Dkr596.76 Million | Dkr343.93 Million | ▼ -48.8 pp |
| 2013 | 91.1% | Dkr316.14 Million | Dkr346.91 Million | Dkr30.77 Million | ▼ -2.9 pp |
| 2012 | 94.0% | Dkr491.01 Million | Dkr522.40 Million | Dkr31.39 Million | ▼ 0.0 pp |
| 2011 | 94.0% | Dkr441.40 Million | Dkr469.48 Million | Dkr28.08 Million | ▲ +3.7 pp |
| 2010 | 90.4% | Dkr407.11 Million | Dkr450.55 Million | Dkr43.44 Million | ▲ +6.6 pp |
| 2009 | 83.8% | Dkr132.92 Million | Dkr158.68 Million | Dkr25.75 Million | ▼ -8.9 pp |
| 2008 | 92.6% | Dkr208.63 Million | Dkr225.24 Million | Dkr16.61 Million | ▲ +0.6 pp |
| 2007 | 92.0% | Dkr242.37 Million | Dkr263.37 Million | Dkr21.00 Million | — |